Protalix BioTherapeutics Q2 EPS $0.21 Beats $(0.04) Estimate, Sales $35.08M Beat $10.22M Estimate
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics reported Q2 earnings of $0.21 per share, beating the analyst consensus estimate of $(0.04) by 625%. The company also reported quarterly sales of $35.08 million, beating the analyst consensus estimate of $10.22 million by 243.25%. This represents a significant increase over the same period last year.
August 07, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protalix BioTherapeutics reported significantly higher Q2 earnings and sales than expected, indicating strong growth.
Protalix BioTherapeutics reported Q2 earnings and sales that significantly beat estimates. This indicates strong growth and could lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100